IRVINE, Calif., March 16, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic […]
INDIANAPOLIS, March 15, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer’s dementia. The original study design included co-primary endpoints of cognition and function—measured by ADAS-Cog14 (Alzheimer’s Disease Assessment Scale-Cognitive subscale) […]
March 8, 2016 – KENILWORTH, N.J. & LYON, France–(BUSINESS WIRE)–Sanofi Pasteur and Merck, known as MSD outside the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their […]
With ixekizumab, most patients who did not respond to treatment with etanercept in a Phase 3 clinical trial achieved virtually clear (Psoriasis Area Severity Index score [PASI] 90) or completely clear skin (PASI 100) after 12 weeks INDIANAPOLIS, March 7, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe […]
Results from the UNCOVER-1 study will also be presented at the American Academy of Dermatology (AAD) Annual Meeting, March 4-8, 2016, in Washington, D.C. INDIANAPOLIS, March 7, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect […]
Application Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival for Patients Taking KEYTRUDA Compared to Chemotherapy in Patients with PD-L1 Expression on One Percent or More of the Cancer Cells March 7, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. […]
March 7, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Sanat Chattopadhyay as executive vice president and president, Merck Manufacturing Division (MMD), effective April 1, 2016. Chattopadhyay will succeed Willie A. Deese who will retire on June 1, 2016 after 12 years with […]
In a combined analysis of UNCOVER-2 and UNCOVER-3, significant improvement of psoriasis plaques was observed in patients treated with ixekizumab at one, two and four weeks INDIANAPOLIS, March 4, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically meaningful improvements as early […]
Since 1987 Merck Has Donated More than Two Billion Treatments of Mectizan to Help Eliminate River Blindness and Lymphatic Filariasis March 4, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company, together with the Mectizan Donation Program, is donating $1 million to the END […]
IRVINE, Calif., March 2, 2016 — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug Administration approval to expand use of the Edwards SAPIEN XT transcatheter heart valve for pulmonic valve replacement procedures. The approval enables the treatment of […]